Question · Q4 2025
Benjamin Briggs sought clarification on the $450 million EBITDA run rate, confirming it includes two new contracts but excludes Midwest Regional. He also asked about the potential EBITDA upside from activating Midwest Regional, the total additional bed capacity including surge, and whether the revolver remains an option for share repurchases.
Answer
David Garfinkle, CFO, confirmed the EBITDA run rate clarification and noted Midwest Regional's $60 million annual revenue, which would be upside to guidance. He also confirmed the 13,000 total additional bed capacity. Regarding share repurchases, he stated that AFFO (approximately $200 million after growth CapEx) is available without increasing leverage, but the revolving credit facility can also be utilized.
Ask follow-up questions
Fintool can predict
CXW's earnings beat/miss a week before the call